Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2003 Oct 28;89(9):1766–1775. doi: 10.1038/sj.bjc.6601346

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2003 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effect of gefitinib on MAP kinase activity in CM cells. CM cells were treated with 10 μM gefitinib for 0–48 h. At the indicated time points, the amount of phosphorylation of ERK1/2 and p38MAP kinases was analysed by Western blotting. (A) Gefitinib induced a time-dependent decrease in phosphorylated ERK1/2. (B) By contrast, no change in p38 MAPK phosphorylation was observed upon treatment with gefitinib.